Loading Events

Join us for the first MedTeCCH Forum for 2022 …

Thursday 17th February 2022

9.30am – 11am (+ morning tea)

Design + Industry Facility

24 Portside Cres, Maryville 2293

REGISTER HERE

Presentations by:

PROFESSOR JENNIFER MARTIN

Clinical Director, Australian Centre for Medicines Development & Advanced Manufacturing Technologies

Physician & Clinical Pharmacologist, HNE & University of Newcastle

Professor Jennifer Martin will overview the new Australian Centre for Medicines Development and Advanced Manufacturing Technologies which, in partnership with her team, she established and is developing from the Hunter region. Professor Martin will highlight the need for drug repurposing in light of the sovereign risk to essential medicines supply in Australia, and overview the potential opportunities for the local advanced manufacturing industry.

JOHN LANCKEN

Head of Design + Industry (D+I) Newcastle

During 2021, D+I worked with Newcastle success story NewieVentures. Recognising complementary skills and principles in the team’s expertise, proven performance, electronics capability, readiness for scaling and positive culture, D+I acquired the business late last year. John will overview D+I, it’s history, capability, track record, client base and impressive body of work. John is enthusiastic about the Newcastle/Hunter spirit of progressive thinking, world-class companies and talent, and potential to be a showcase Smart City for Australia and will touch on D+I’s vision for the Newcastle arm of the company.

 ANDREW ADAMOVICH

Managing Director, AdvanCell

DR MIKE FAY

Chief Medical Officer, AdvanCell

AdvanCell Isotopes is a NSW based radiopharmaceutical company developing next-generation cancer treatments. AdvanCell’s portfolio of targeted alpha therapies is powered by a platform technology – a world-first alpha isotope generator – which addresses the greatest unmet need in targeted alpha therapy – the reliable and scalable supply of isotope. Targeted Alpha Therapies demonstrate incredible efficacy, however widespread adoption and large commercial product launches require a scalable and reliable global isotope supply.

AdvanCell Isotopes was established to solve this problem – a novel approach enables the supply of alpha emitting isotopes at the scale required to rapidly execute clinical trials and support commercial launch of a pipeline of targeted alpha therapies across multiple indications.

During the presentation, Andrew Adamovich and AdvanCell’s CMO Dr Mike Fay will provide an overview of the development of company’s Isotope generator, which shares some strong bonds within the Hunter region.

 ANDREW SARGEANT

Director Point of Care Testing, NSW Heath Pathology

Opportunities for Hunter Central Coast industry to collaborate with NSW Health Pathology Point of Care Testing

REGISTER HERE

Share This Story, Choose Your Platform!

Go to Top